医策科技王晓梅：以技术创新与全球视野深化业务布局

Group 1 - The company aims to address the significant supply-demand imbalance in the domestic pathology field, where there are only 21,000 pathologists nationwide, equating to 14.8 per million people, and a shortage of specialized pathology analysts in drug research [1] - The core strategy is to upgrade pathology AI from an "efficiency tool" to a "capability tool," enabling AI to serve as a "super assistant" with professional decision-making abilities [1][2] - The company is accelerating the implementation of AI-assisted pathology diagnosis in various scenarios, including integrating AI analysis into hospital reporting processes and providing low-cost access to AI capabilities for grassroots healthcare [2] Group 2 - By 2026, the company plans to solidify its core businesses in pharmaceutical research pathology CRO services and medical diagnostic pathology AI solutions, focusing on technological innovation and global expansion [3] - The company has developed the world's first digital pathology CRO platform for pharmaceutical research, providing end-to-end digital processes from sample to report, supporting high-impact quantitative and semi-quantitative analysis [3] - The product line will cover all disciplines of AI products, including cellular, tissue, immune, and molecular, with the "Lingmou" multimodal pathology model already applied in numerous medical institutions domestically and internationally [3]